重组人白介素-11联合环孢素治疗糖皮质激素无效ITP的临床疗效

顾惠慈

（江苏省海门市人民医院血液科，江苏 海门，226100）

浏览次数：210次 下载次数：328次

摘要：

目的 探讨研究重组人白介素-11联合环孢素治疗糖皮质激素无效ITP的临床疗效。方法 选取我院收治的42例糖皮质激素无效ITP患者为研究对象，随机将其分为研究组和对照组，各21例。研究组患者采用重组人白介素-11联合环孢素治疗；对照组患者采用长春新碱联合人免疫球蛋白治疗。分别比较两组患者治疗前和治疗7、10、14、21 天和1、3、5 个月及1 年后的血小板计数，并在治疗1、3、5 个月及1 年后比较两组的患者的临床疗效。结果 治疗前和治疗4 天后两组的血小板计数差异均不显著（P>0.05）；治疗7、10、14、21 d，1、3、5 个月及1年后，研究组患者的血小板计数均显著高于对照组（P<0.05）。治 疗1、3、5 个月及1 年后，研究组患者的临床总有效率均显著高于对照组（P<0.05）。结论 采用重组人白介素-11联合环孢素治疗糖皮质激素无效ITP 安全有效，值得临床推广。

关键词：重组人白介素-11；环孢素；ITP

中图分类号：R558.2文献标志码：A文章编号：2096-1413(2017)19-0023-02

Clinical effect of recombinant human interleukin-11 combined with cyclosporine in the treatment of

glucocorticoid invalid ITP
GU Hui-ci
(Department of Hematology, Haimen People``s Hospital of Jiangsu, Haimen 226100, China)

ABSTRACT: Objective To investigate the clinical efficacy of recombinant human interleukin -11 combined with cyclosporine in the treatment of glucocorticoid invalid ITP. Methods Forty-two glucocorticoid invalid ITP patients admitted in our hospital were selected and randomly divided into study group and control group, with 21 cases in each group. The study group was treated with recombinant human interleukin-11 combined with cyclosporine, and the control group received vincristine combined with immunoglobulin. The platelet count of the two groups before treatment and 7 days, 10 days, 14 days, 21 days, 1 month, 3 months, 5 months and 1 year after treatment were compared. The clinical effects of the two groups 1 month, 3 months, 5 months and 1 year after treatment were compared. Results There was no significant difference on platelet count before treatment and 4 days after treatment between the two groups (P>0.05). At 7 days, 10 days, 14 days, 21days, 1 month, 3 months, 5 months and 1 year after treatment, the platelet count of the study group were better than those of the control group (P<0.05). At 1 month, 3 months, 5 months and 1 year after treatment, the total effective rate of the study group were higher than those of the control group (P<0.05). Conclusion Recombinant human interleukin-11 combined with cyclosporine in the treatment of glucocorticoid invalid ITP is safe and effective, which is worthy of promotion in clinic.
KEYWORDS: recombinant human interleukin -11; cyclosporine; primary immune thrombocytopenia (ITP)

参考文献：
[1] 李洪琴,陈波,江桂林,等.中药联合重组白介素-11治疗难治性特发性血小板减少性紫癜的临床观察和护理[J].实用临床医药杂志,2014,18(22):31-34.
[2] 季美华,马海佳,陈进,等.重组人白介素-11 联合激素治疗重症成人原发免疫性血小板减少症的短期临床疗效观察[J].中国医刊,2015,50(2):95-97.
[3] 庄万传,江亚军,李秀梅,等.重组人白介素-11 联合环孢素治疗糖皮质激素无效ITP 的临床研究[J].安徽医学,2015,36(9):1065-1067.
[4] 毛小俞.重组人白介素-11 治疗难治性特发性血小板减少症的临床分析[J].中外医疗,2014,33(21):80-81.
[5] 寇宏,熊安秀,王敏.白介素11 联合糖皮质激素治疗儿童慢性小板减少性紫癜的疗效及其免疫功能的研究[J].临床和实验医学杂志,2014,13(13):1123-1125.
[6] 田秋生.长春新碱联合重组人白介素-11治疗难治性特发性血小 板减少性紫癜的临床疗效[J].中国卫生标准管理,2014,5(14):1-2.